Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The serum apoE levels in 238 healthy adults in Chengdu are aware determined by radioimmunodiffusion (RID) assay. The average apoE level was 3.98 +/- 0.98 mg/dl (chi +/- s). The result was basically identical with other reports. There is no difference in sex, and the level has a tendency to increase with age. One hundred and sixty-one hyperlipidemic subjects (including types IIa, IIb, IV and V were compared with the normals. Their serum apoE levels increased by different percentages depending on the type of hyperlipidemia. The percentage of increasing was especially higher in types V and IIb. The content of apoE in serum positively correlated with serum triglyceride (r = 0.65, P < 0.01) and with serum total cholesterol (r = 0.50, P < 0.01).
Hua Xi Yi Ke Da Xue Xue Bao 1992 Sep
PMID:[Serum apolipoprotein E levels in 238 healthy adults and 161 hyperlipidemic subjects in Chengdu area]. 129 13

Malondialdehyde-modified-low density lipoprotein (MDA-LDL), lipid peroxide (LPO), lipid and fasting blood glucose (FBG) were studied in 42 diabetic patients and 20 age-matched controls. The results revealed that both MDA-LDL per L serum and MDA-LDL per mol LDL-C of diabetics were higher than those of controls. MDA-LDL/L tended to be much higher in diabetic patients with vascular disease and hyperlipidemia. There was a positive correlation between MDA-LDL/L and LPO, LDL-C, TC, respectively.
Hua Xi Yi Ke Da Xue Xue Bao 1991 Mar
PMID:[Malondialdehyde-modified-low density lipoprotein in diabetes mellitus]. 177 47

A radial immunodiffusion assay (RID) for quantitation of human serum apolipoprotein CII (apoCII) was developed. Antiserum to apoCII was raised in goats with purified apoCII. The antibody-gel plate was prepared with 1% agarose. 5 microliters of each sample or standard serum was added in a well. Diffusion was performed at 25 degrees C or 37 degrees C for 48 h. The standard curve with a working range of 0.8-4.5 mg/dl was plotted. The minimum measurable concentration of apoCII was 40 ng. The intra-assay and inter-assay CV were 1.4-3.5% and 1.3-3.6% respectively. The recovery of the assay was 92.38-104.35%. The concentrations of apoCII for healthy adults and patients with hyperlipidemia were 3.9 +/- 1.7 mg/dl (M +/- SD, n = 67) and 5.9 +/- 2.5 mg/dl (n = 43) respectively.
Hua Xi Yi Ke Da Xue Xue Bao 1989 Dec
PMID:[Quantitation of human serum apolipoprotein CII by radial immunodiffusion assay]. 251 21

The effect of Olbetam on serum lipid and lipoproteins was studied in 30 diabetic patients with hyperlipidemia in four weeks trial. The dose of Olbetram was 500 mg/d. The results showed serum concentrations of TC, TG, and VLDL-C were decreased while HDL-C especially HDL2-C increased significantly after treatment. There were no significant changes in FBG, blood creatinine and urine acid. This result suggests Olbetam can improve dyslipidemia in NIDDM and was well tolerated by all patients.
Hua Xi Yi Ke Da Xue Xue Bao 1995 Dec
PMID:[Effect of olbetam on hyperlipidemia in NIDDM]. 873 67

It has been evidenced that cardiovascular diseases (CVD) relate with many risk factors and serum lipids play and essential role in the development of CVD. In order to further study hyperlipidemia (HL) in the middle-aged males, we analysed the body mass index (BMI), fast blood sugar (FBS), serum lipids and apolipoproteins A I, A II, B100, C II, C III and E in 223 male HL patients aged 41-60 and 349 normal male subjects who matched the HL patients in age. The result showed that the increase of serum triglycerids (TG), was as might be expected, the major characteristic of the middle-aged male HL patients in Chengdu District. Besides the serum lipid and apolipoprotein B100, C II, C III and E levels, the BMI and FBS levels in the IIb, IV and V types of HL patients were significantly higher than those in the normal subjects. It also showed that in TG increased patients the increased percentages of serum lipids were significantly higher than those of apolipoproteins. The age distribution in HL patients revealed that only 25% of the HL patients were between 41 to 50 years old, while 50% in the 56-60 year-old group. The relationship between apolipoprotein levels and serum lipid metabolism is also discussed. The results suggest that the 51-60 year-old males should pay attention to diet and increase physical activities to reduce incidence of HL which is directly associated with CVD.
Hua Xi Yi Ke Da Xue Xue Bao 1997 Mar
PMID:[The serum lipid and apolipoprotein levels of middle-aged male hyperlipidemics in Chengdu district]. 1068 53

This study was directed at the effects of lovastatin on plasma glucose and insulin metabolism of patients with Type II B hyperlipemia. Thirty patients with Type II B hyperlipemia were observed. At the beginning, We detected the patients' TC, TG, HDL-C, VLDL-C with enzyme assay, calculated their LDL-C with formula, determined their plasmaglucose(PG) with oxidase assay and plasma insulin(PI) with immunoradioassay, and then we performed OGTT and insulin release test, these indices were detected again after the administration of 8 weeks' lovastatin therapy (20 mg per day). The results showed that, aftert the therapy, TC and LDL-C decreased significantly(P < 0.05), TG, HDL-C and VLDL-C had no significant change(P > 0.05). Fasting plasma glucose(FPG) and fasting plasma insulin(FPI) increased (the former, P < 0.05). Two hours after administration of glucose, the level of plasma glucose(2hPG) and plasma insulin(2hPI)increased(the latter, P < 0.05). 1/(FPG x FPI) had no significant change, but 1/(2hPG x 2hPI) decreased (P < 0.05). These data indicate that long-period use of lavastatin may cause insulin resistance. So we advise patients with Type II B hyperlipemia treated by statin to limit their glucose intake in case of hyperinsulinemia and insulin resistance.
Hua Xi Yi Ke Da Xue Xue Bao 1999 Dec
PMID:[Effects of lovastatin on plasma lipid, plasma glucose and insulin metabolism of patients with type II B hyperlipemia]. 1138 65

Hyperlipidemia, type 2 diabetes mellitus, nonalcoholic fatty liver and many other metabolic disorder are frequently co-existing in patients. In addition, these diseases are closely related in pathophysiological settings. However, increasing of the disease incidence, lacking of comprehensive prevention and control measurements against the key pathology point concomitant occurrence with the pattern of the single disease, single target therapy, that is leading therapeutic strategy for these metabolic disorders in the setting of Western medicine (WM). On the basis of the combination of the advantages of integrated Chinese medicine (CM) and WM, with unified understanding of such diseases, the new concept of glucolipid metabolic disease (GLMD) is introduced. In this new concept, disorders in glucose and lipid metabolism are recognized as the key trigger and major driving force for the progress of GLMD. The key points of pathology included dysfunction of neuronal-endocrine-immune system, insulin resistance, oxidative stress, inflammation and intestinal flora imbalance. In the core pathogenic perspective of CM, it can be explained as "Gan (Liver) Shi Shu Xie" (dysfunction of Gan in metabolism and emotion regulation) that will lead to the occurence/production of endogenous dampness and phlegm, blood stasis and turbid. This leads to the new concept of "Liver-based regulatory system for metabolic homeostasis" to be introduced further. The comprehensive prevention and control strategy "Tiao Gan Qi Shu Hua Zhuo" (modulating Gan, trigging key metabolic system to resolve pathogenic factors such as phlegm retention and dampness). Its representative formula Fufang Zhenzhu Tiaozhi Capsule () is innovated under such rationales. Comment for some commonly-used CM GLMD therapeutic drugs was presented. High-level evidence-based and epidemiological and mechanism studies should be carried out to further interpret and explain of the scientific connotation of GLMD.
 ...
PMID:Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. 2879 81